Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
1995 3
1996 1
1997 2
1998 6
1999 5
2000 6
2002 1
2003 1
2004 5
2005 6
2006 2
2007 5
2008 9
2009 10
2010 20
2011 23
2012 10
2013 10
2014 22
2015 20
2016 24
2017 14
2018 8
2019 10
2020 15
2021 26
2022 24
2023 9
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative therapies for urological cancers.
Inokuchi J, Yokomizo A, Nishiyama N, Kitamura H, Eto M, Nishiyama H, Tomita Y. Inokuchi J, et al. Among authors: yokomizo a. Jpn J Clin Oncol. 2020 Apr 7;50(4):357-367. doi: 10.1093/jjco/hyaa013. Jpn J Clin Oncol. 2020. PMID: 32115649 Review.
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study.
Shiota M, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Sekine Y, Kimura H, Narita S, Terada N, Momozawa Y, Akamatsu S, Habuchi T, Yokomizo A, Naito S, Eto M. Shiota M, et al. Among authors: yokomizo a. Endocr Relat Cancer. 2023 Jun 1;30(7):e230044. doi: 10.1530/ERC-23-0044. Print 2023 Jul 1. Endocr Relat Cancer. 2023. PMID: 37079309
Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer.
Shiota M, Takamatsu D, Kimura T, Tashiro K, Matsui Y, Tomida R, Saito R, Tsutsumi M, Yokomizo A, Yamamoto Y, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Narita S, Matsumoto R, Kasahara T, Hashimoto K, Matsumoto H, Kato M, Akamatsu S, Joraku A, Kato M, Yamaguchi T, Saito T, Kaneko T, Takahashi A, Kato T, Sakamoto S, Enokida H, Kanno H, Terada N, Suekane S, Nishiyama N, Eto M, Kitamura H; Japanese Urological Oncology Group. Shiota M, et al. Among authors: yokomizo a. Cancer Sci. 2022 Jul;113(7):2386-2396. doi: 10.1111/cas.15383. Epub 2022 May 17. Cancer Sci. 2022. PMID: 35485635 Free PMC article.
How to peer review.
Christensen NB, Yokomizo A. Christensen NB, et al. Among authors: yokomizo a. Int J Urol. 2010 Sep;17(9):754. doi: 10.1111/j.1442-2042.2010.02622.x. Int J Urol. 2010. PMID: 20727046 No abstract available.
The I.3.2 developmental mutant has a single nucleotide deletion in the gene centromere identifier.
Evans CJ, Bieser KL, Acevedo-Vasquez KS, Augustine EJ, Bowen S, Casarez VA, Feliciano VI, Glazier A, Guinan HR, Hallman R, Haugan E, Hehr LA, Hunnicutt SN, Leifer I, Mauger M, Mauger M, Melendez NY, Milshteyn L, Moore E, Nguyen SA, Phanphouvong SC, Pinal DM, Pope HM, Salinas MM, Shellin M, Small I, Yeoh NC, Yokomizo AMK, Kagey JD. Evans CJ, et al. Among authors: yokomizo amk. MicroPubl Biol. 2022 Oct 25;2022:10.17912/micropub.biology.000653. doi: 10.17912/micropub.biology.000653. eCollection 2022. MicroPubl Biol. 2022. PMID: 36389120 Free PMC article.
Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Dote S, Shiwaku E, Kohno E, Fujii R, Mashimo K, Morimoto N, Yoshino M, Odaira N, Ikesue H, Hirabatake M, Takahashi K, Takahashi M, Takagi M, Nishiuma S, Ito K, Shimato A, Itakura S, Takahashi Y, Negoro Y, Shigemori M, Watanabe H, Hayasaka D, Nakao M, Tasaka M, Goto E, Kataoka N, Yokomizo A, Kobayashi A, Nakata Y, Miyake M, Hayashi Y, Yamamoto Y, Hirata T, Azuma K, Makihara K, Fukui R, Tokutome A, Yagisawa K, Honda S, Meguro Y, Suzuki S, Yamaguchi D, Miyata H, Kobayashi Y; IMBERA Investigators. Dote S, et al. Among authors: yokomizo a. Int J Clin Oncol. 2023 Aug;28(8):1054-1062. doi: 10.1007/s10147-023-02357-3. Epub 2023 Jun 1. Int J Clin Oncol. 2023. PMID: 37261583 Free PMC article.
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.
Minami K, Osawa T, Kojima T, Hara T, Eto M, Takeuchi A, Nakai Y, Ueda K, Ozawa M, Uemura M, Ohba K, Tamura K, Shindo T, Nakagomi H, Takahashi A, Anai S, Yokomizo A, Morizane S, Kimura T, Shimazui T, Miyauchi Y, Mitsuzuka K, Hara H, Yoshimura K, Shiina H, Ito YM, Murai S, Nishiyama H, Shinohara N, Kitamura H; Japanese Urological Oncology Group. Minami K, et al. Among authors: yokomizo a. Urol Oncol. 2023 Nov;41(11):458.e9-458.e19. doi: 10.1016/j.urolonc.2023.08.008. Epub 2023 Oct 3. Urol Oncol. 2023. PMID: 37798145
256 results